Please login to the form below
payer
This page shows the latest payer news and features for those working in and with pharma, biotech and healthcare.
Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
The increasing availability and adoption of biosimilars means these treatments are delivering on the fundamental promise of reducing healthcare costs for payers, employers and patients in the United States,” she said.
Latest news
-
Embattled Biogen talks up Aduhelm
The company even requested a narrowing of the indication to reduce the impact on payers' budgets, after estimates placed the bill for Medicare at $29bn for a single year. ... The Department for Veteran’s Affairs (VA) – a crucial payer for the drug in
-
J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
Among the anticompetitive practices that Pfizer accused J&J of was contracting with payers and providers to prevent use of Inflectra, with Remicade payer contracts allegedly written to deny reimbursement for
-
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
How to demonstrate value to regulators and payers? In order to secure regulatory approval, manufacturers need to clearly demonstrate TA products are safe and efficacious. ... Manufacturers need to demonstrate value to both. Earlier this year we spoke to
-
Biogen plans confirmatory trial as FDA documents show struggle over Aduhelm approval
They added: “In the event that our fundamental assumptions on population size and rate of adoption are significantly different than expected, we stand ready to work with public and private payers
-
Nature's way
Firstly, governments and other payers have been slow to evolve their capability to signal to innovators what they value. ... Combine recent emergence, payer platitudes and primitive science and we are better able to understand why about two-thirds of the
Embattled Biogen talks up Aduhelm
J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
Nature's way
More from news
Approximately 6 fully matching, plus 594 partially matching documents found.
Latest Intelligence
-
Nudging someone in the right direction isn’t always easy – that’s where behavioural science comes in
Essentially, it is about unearthing what truly makes people tick – healthcare professionals, patients, carers, payers or any other stakeholder – and developing tangible actions and interventions to effectively nudge their behaviours to
-
Patient-centred drug development: how far have we come and what’s next?
Studies have already shown that drugs developed using patient-centric clinical trials are up to 19% more likely to launch and be more quickly adopted by payers.
-
Understanding the ‘real world’ starts and ends with the patient
clinical outcome is and make it suitable for both regulators and payers.
-
Communicating for change – creating effective medical communications
Physicians, advance practice providers, payers and of course patients are all legitimate stakeholders whom we must reach and involve in discussions about optimal care. ... I’d say yes because effective commercial evidence evaluation and planning better
-
Recruiting patients for real-world studies – the power of a digital campaign
By Will Maier. Increasingly, real-world evidence – information gathered as a product to be used in clinical practice – helps regulators, payers, providers and patients make informed health decisions.
Nudging someone in the right direction isn’t always easy – that’s where behavioural science comes in
Patient-centred drug development: how far have we come and what’s next?
Understanding the ‘real world’ starts and ends with the patient
Communicating for change – creating effective medical communications
Recruiting patients for real-world studies – the power of a digital campaign
More from intelligence
Approximately 5 fully matching, plus 259 partially matching documents found.
Latest appointments
-
VMLY&Rx launches new payer agency in the US
VMLY&Rx Payer will be helmed by healthcare comms industry veteran HeeSun Yu. ... Payers and population health decision makers (PHDM) are the gatekeepers to healthcare in the US.
-
Syneos Health appoints trio of senior hires
He has worked on multiple brands and therapeutic categories and has omnichannel expertise across patients, providers and payers.
-
Christie Anbar appointed global healthcare lead at Ruder Finn
organisations and payer and hospital systems.
-
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
They also have additional experience of the challenges in an evolving payer environment, gained in prior roles in the NHS, the pharma industry and market access consulting.
-
Open Access Consulting appoints new director
In this role, Hurrell oversaw the team’s market access communications offering, supporting clients in the development of value communications materials with the payer as the ultimate end audience, including core ... value dossiers, payer-focused
VMLY&Rx launches new payer agency in the US
Syneos Health appoints trio of senior hires
Christie Anbar appointed global healthcare lead at Ruder Finn
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
Open Access Consulting appoints new director
More from appointments
Approximately 0 fully matching, plus 23 partially matching documents found.
Latest from PMHub
-
Ashfield to host webinar on Patient Support Programmes on Tuesday 10 October
Patients, payers and healthcare professionals have high expectations for patient support programmes (PSPs).
-
Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19).
-
Market Access Transformation (MAT) Secures First Institutional Funding Led by Silversmith Capital Partners
Founded in 2016, MAT has revolutionized the way Global Payer Market Research is conducted by developing Rapid Payer Response (RPR), the industry’s only on-demand global platform for gathering critical ... RPR is powered by an expansive global payer
-
What do NHS changes and the Life Sciences Vision mean for medicines?
Rare disease, advanced and specialist therapies have sometimes been seen as a burden for payers focused on other bigger priorities for larger patient populations.
-
Wedgewood Communications joins imc group to expand its presence in the US market
About imc group:. imc group is a leading, independent global healthcare communication group that enables clients’ brands to connect with healthcare professionals, payers and patients through transformative end-to-end solutions,
What do NHS changes and the Life Sciences Vision mean for medicines?
More from PMHub
Approximately 6 fully matching, plus 135 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
No results were found
PMHub
Madmicrobe Studios - Medical Animation
MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
